Summary
Methylprednisolone hemisuccinate (MPS) and methylprednisolone (MP) concentrations in plasma and urine were monitored in renal transplant and glomerulonephritis patients who were given i.v. infusions of 0.5 g or 1 g of MPS. A marked individual variation of peak plasma levels of both MPS and MP was observed after the same dose and MPS disappeared from plasma more rapidly than MP. Their clearances from the circulation, however, did not appear to be significantly influenced by the peak plasma levels of the drug, creatinine clearance, administration of previous pulses of MPS or the urinary excretion of unconjugated MPS and MP. Even in patients with profoundly reduced renal function, no accumulation of the drug was apparent when repeated doses of MPS were administered at 48-h intervals.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Williams IA, Baylis EM, Shipley ME (1982) A double-blind placebo-controlled trial of methylprednisolone pulse therapy in active rheumatoid disease. Lancet 2: 237–240
Turcote J, Feduska N, Carpenter F, McDonald F, Bacon G (1972) Rejection crises in human renal transplant recipients. Arch Surg 105: 230–236
Editorial (1977) The big shot. Lancet 1: 633–634
Gray D, Daar A, Shepherd H, Oliver BO, Morris P (1978) Oral vs intravenous high-dose steroid treatment of renal allograft rejection. The big shot or not. Lancet 1: 117–120
Mussche MM, Ringoir SMG, Lameire NN (1976) High intravenous doses of methylprednisolone for acute cadaveric renal allograft rejection. Nephron 16: 287–291
Assael BM, Banli G, Appiani AC, Edfonti A, Juskow I (1982) Disposition of pulse dose methylprednisolone in adult and paediatric patients with nephrotic syndrome. Eur J Clin Pharmacol 23: 429–433
Baylis EM, Williams IA, English JA, Marks V, Chakraborty J (1982) High-dose intravenous methylprednisolone ‘pulse’ therapy in patients with rheumatoid disease. Eur J Clin Pharmacol 21: 385–388
Solu-Medrol Bioavailability Study, protocol CS 002 (1977) From: A profile of Solu-Medrol. Upjohn Company, Kalamazoo, MI, USA, pp 21–22
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Searle, M., Lawson, G., Chakraborty, J. et al. High-dose methylprednisolone sodium succinate (pulse therapy) in the treatment of renal disease: Plasma and urine concentrations. Eur J Clin Pharmacol 28, 245–248 (1985). https://doi.org/10.1007/BF00543317
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00543317